Pliant Therapeutics (PLRX) EBITDA (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly EBITDA of -$21.8 million for Q1 2026, up 63.06% year-over-year from -$13.4 million in Q1 2025, and up 7.66% quarter-over-quarter from -$23.6 million in Q4 2025.
Pliant Therapeutics (PLRX) EBITDA (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported EBITDA for 8 consecutive years, with -$21.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 63.06% year-over-year to -$21.8 million; the TTM figure through Mar 2026 stood at -$119.2 million (up 49.25% YoY), while the FY2025 annual figure was -$156.4 million, up 31.52% from the prior year.
- EBITDA grew to -$21.8 million in Q1 2026 per PLRX's latest filing, from -$23.6 million in the prior quarter.
- Across five years, EBITDA topped out at -$21.8 million in Q1 2026 and bottomed at -$62.0 million in Q3 2024.
- Historically, EBITDA has averaged -$42.2 million across 5 years, with a median of -$45.6 million in 2025.
- Annual changes were most pronounced in 2023 — EBITDA plunged 59.67% — and 2026, when it jumped 63.06%.
- Pliant Therapeutics' EBITDA stood at -$37.4 million in 2022, then slipped by 25.77% to -$47.0 million in 2023, then declined by 13.36% to -$53.3 million in 2024, then jumped by 55.78% to -$23.6 million in 2025, then climbed by 7.66% to -$21.8 million in 2026.
- Business Quant data shows PLRX's EBITDA at -$21.8 million in Q1 2026, -$23.6 million in Q4 2025, and -$28.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | -23.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.86 Mn |
| Mar 31, 2026 | -21.77 Mn |
| Dec 31, 2025 | -23.58 Mn |
| Sep 30, 2025 | -28.27 Mn |
| Jun 30, 2025 | -45.59 Mn |
| Mar 31, 2025 | -58.94 Mn |
| Dec 31, 2024 | -53.32 Mn |
| Sep 30, 2024 | -62.01 Mn |
| Jun 30, 2024 | -60.64 Mn |
| Mar 31, 2024 | -52.39 Mn |
| Dec 31, 2023 | -47.04 Mn |
| Sep 30, 2023 | -47.69 Mn |
| Jun 30, 2023 | -47.33 Mn |
| Mar 31, 2023 | -42.10 Mn |
| Dec 31, 2022 | -37.40 Mn |
| Sep 30, 2022 | -31.95 Mn |
| Jun 30, 2022 | -29.64 Mn |
| Mar 31, 2022 | -28.21 Mn |
| Dec 31, 2021 | -24.60 Mn |
| Sep 30, 2021 | -27.11 Mn |